Theresa Abdo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Theresa Abdo has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Zeina Nahleh
Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA
4 shared publications - Ahmad Alhalabi
Department of Hematology and Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
2 shared publications Rami Tfayli
Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL
2 shared publications- Shashi Kant
Department of Hematology and Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
2 shared publications - Aaron Sidhu
Department of Hematology and Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
1 shared publication Ahmad Alhalabi
Department of Hematology and Oncology Cleveland Clinic Florida Maroone Cancer Center Weston Florida USA
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 687
Factors Influencing Engagement in Psycho-Oncology Services at a Comprehensive Cancer Center
Background: Psychological distress is common among cancer patients, yet some patients referred to psycho-oncology services do not engage in care. Identifying factors associated with engagement may improve supportive care access and reduce disparities. We evaluated sociodemographic and clinical predictors of psychotherapy utilization among patients referred by oncologists or self-referred to psycho-oncology. Methods: We retrospectively reviewed adults with cancer referred to psycho-oncology services between December 2022 and August 2024, with follow-up through December 2025. The primary outcome was attendance versus nonattendance at the initial psychotherapy appointment. Secondary analysis evaluated total psychotherapy visits. Logistic regression and negative binomial regression identified predictors of initial attendance and subsequent utilization, respectively. Results: Among 404 eligible patients, 98 (24.3%) attended no appointments. Median utilization was 2 visits (IQR, 1–5) over 25.7 months (IQR, 15.1–34.1) of follow-up. In multivariable analysis, nonattendance was associated with lack of religious affiliation (Adjusted OR (aOR), 22.7; 95% CI, 8.52–60.5), less than college education (aOR, 7.56; 95% CI, 2.99–19.3), and referral for anxiety alone (aOR, 4.47; 95% CI, 1.72–11.6), depression alone (aOR, 4.15; 95% CI, 1.19–14.4), or other indications (aOR, 34.8; 95% CI, 9.39–129.1) versus combined anxiety and depression (all p ≤ 0.03). Higher visit rates were associated with virtual visits (Incidence rate ratios (IRR), 2.92; 95% CI, 2.20–3.89), physician referral (IRR, 2.05; 95% CI, 1.49–2.81), later referral, religious affiliation (IRR, 4.05; 95% CI, 2.79–5.88), anxiety/depression referral, and targeted therapy (all p < 0.01). Conclusions: Psycho-oncology engagement varies by educational, social, clinical, and referral factors. Telehealth was associated with greater utilization, while referral timing and source may represent modifiable targets for improving engagement and access to supportive care.
- 9 November 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 687
Open AccessFactors Influencing Engagement in Psycho-Oncology Services at a Comprehensive Cancer Center
Background: Psychological distress is common among cancer patients, yet some patients referred to psycho-oncology services do not engage in care. Identifying factors associated with engagement may improve supportive care access and reduce disparities. We evaluated sociodemographic and clinical predictors of psychotherapy utilization among patients referred by oncologists or self-referred to psycho-oncology. Methods: We retrospectively reviewed adults with cancer referred to psycho-oncology services between December 2022 and August 2024, with follow-up through December 2025. The primary outcome was attendance versus nonattendance at the initial psychotherapy appointment. Secondary analysis evaluated total psychotherapy visits. Logistic regression and negative binomial regression identified predictors of initial attendance and subsequent utilization, respectively. Results: Among 404 eligible patients, 98 (24.3%) attended no appointments. Median utilization was 2 visits (IQR, 1–5) over 25.7 months (IQR, 15.1–34.1) of follow-up. In multivariable analysis, nonattendance was associated with lack of religious affiliation (Adjusted OR (aOR), 22.7; 95% CI, 8.52–60.5), less than college education (aOR, 7.56; 95% CI, 2.99–19.3), and referral for anxiety alone (aOR, 4.47; 95% CI, 1.72–11.6), depression alone (aOR, 4.15; 95% CI, 1.19–14.4), or other indications (aOR, 34.8; 95% CI, 9.39–129.1) versus combined anxiety and depression (all p ≤ 0.03). Higher visit rates were associated with virtual visits (Incidence rate ratios (IRR), 2.92; 95% CI, 2.20–3.89), physician referral (IRR, 2.05; 95% CI, 1.49–2.81), later referral, religious affiliation (IRR, 4.05; 95% CI, 2.79–5.88), anxiety/depression referral, and targeted therapy (all p < 0.01). Conclusions: Psycho-oncology engagement varies by educational, social, clinical, and referral factors. Telehealth was associated with greater utilization, while referral timing and source may represent modifiable targets for improving engagement and access to supportive care.
- Open Access
Quality-of-Life and Weight Loss Outcomes Following an Individualized Nutrition and Physical Activity Counseling Program in Breast Cancer Survivors: A Prospective Single-Arm Pilot Study
Purpose: Assess the feasibility of a 6-month individualized nutrition counseling and exercise program targeting a 10% body weight loss in breast cancer (BC) survivors, with secondary endpoints assessing metabolic parameters, cardiovascular function, and quality of life. Methods: This single-arm pilot study enrolled BC survivors with body mass index (BMI) ≥ 25 kg/m2 in a counseling program with a registered dietitian, consisting of in-person and telephone visits over six months. Outcomes measured included weight, body composition, blood markers, cardiovascular function, and quality of life at 3 and 6 months. Results: A total of 78 breast cancer survivors were enrolled; 59 remained in the study at Month 3, and 54 completed the 6-month follow-up. The median age of participants was 58.5 years, and the cohort was predominantly White (72.4%). Among the 54 participants who completed 6-month follow-up, 11.1% achieved >10% weight loss and 29.6% achieved >5% weight loss. At 3 months, significant reductions were observed in BMI, body fat composition, and hemoglobin A1c (HbA1c), along with improvements in quality of life, depression, and anxiety. At 6 months, significant reductions were observed in weight, BMI, and body fat composition, with improvements in quality of life and depressive symptoms. Conclusions: This hybrid nutrition and exercise program was associated with observed improvements in weight loss and improved quality of life among BC survivors. Implications for Cancer Survivors: A low-burden, hybrid nutrition and exercise program integrated into routine oncology follow-up may help breast cancer survivors achieve weight loss while improving their quality of life.
Open AccessQuality-of-Life and Weight Loss Outcomes Following an Individualized Nutrition and Physical Activity Counseling Program in Breast Cancer Survivors: A Prospective Single-Arm Pilot Study
Purpose: Assess the feasibility of a 6-month individualized nutrition counseling and exercise program targeting a 10% body weight loss in breast cancer (BC) survivors, with secondary endpoints assessing metabolic parameters, cardiovascular function, and quality of life. Methods: This single-arm pilot study enrolled BC survivors with body mass index (BMI) ≥ 25 kg/m2 in a counseling program with a registered dietitian, consisting of in-person and telephone visits over six months. Outcomes measured included weight, body composition, blood markers, cardiovascular function, and quality of life at 3 and 6 months. Results: A total of 78 breast cancer survivors were enrolled; 59 remained in the study at Month 3, and 54 completed the 6-month follow-up. The median age of participants was 58.5 years, and the cohort was predominantly White (72.4%). Among the 54 participants who completed 6-month follow-up, 11.1% achieved >10% weight loss and 29.6% achieved >5% weight loss. At 3 months, significant reductions were observed in BMI, body fat composition, and hemoglobin A1c (HbA1c), along with improvements in quality of life, depression, and anxiety. At 6 months, significant reductions were observed in weight, BMI, and body fat composition, with improvements in quality of life and depressive symptoms. Conclusions: This hybrid nutrition and exercise program was associated with observed improvements in weight loss and improved quality of life among BC survivors. Implications for Cancer Survivors: A low-burden, hybrid nutrition and exercise program integrated into routine oncology follow-up may help breast cancer survivors achieve weight loss while improving their quality of life.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Immersive Virtual Reality for the Management of Chemotherapy-Induced Distress in Patients With Cancer
Purpose: Patients with cancer face high levels of distress, anxiety, depression, and pain, often exacerbated during chemotherapy. This pilot trial evaluated the preliminary effect of immersive virtual reality (VR) on these symptoms compared with standard of care (SOC). Methods: In this two-arm randomized controlled trial, participants were allocated 1:1 to a one-time 15-minute VR session or SOC referring to the participant's choice of available activity like watching television during chemotherapy. The primary objective was to assess the effect of VR on distress levels compared with the SOC group. Secondary objectives included assessing the preliminary effects of VR on anxiety, pain, and depressive symptoms, compared with the SOC group. Validated questionnaires were administered to both groups before and after the intervention. Outcomes were analyzed using analysis of covariance models adjusting for baseline values, age, and sex. SAS Studio 3.7 and R version 4.2 were used. Results: Sixty-eight participants completed the study (33 VR, 35 SOC). After adjustment for baseline distress, age, and sex, the VR group had significantly lower postintervention distress scores than the SOC group (adjusted mean difference 1.4 points, 95% CI, 0.34 to 2.45; P = .0102). The VR group had significantly lower postintervention depression and pain scores than the SOC group (adjusted mean differences: 1.14, P = .0055; and 1.5, P = .0032, respectively). Adjusted anxiety scores were lower with VR than SOC but did not reach statistical significance (mean difference 1.76; P = .0815). Conclusion: VR is a safe, innovative immersive intervention with the potential to reduce distress, pain, and depressive symptoms during chemotherapy. Larger longitudinal studies are needed to determine the optimal duration and frequency needed to reduce anxiety and maximize the durability of its effects.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Immersive Virtual Reality for the Management of Chemotherapy-Induced Distress in Patients With Cancer
Purpose: Patients with cancer face high levels of distress, anxiety, depression, and pain, often exacerbated during chemotherapy. This pilot trial evaluated the preliminary effect of immersive virtual reality (VR) on these symptoms compared with standard of care (SOC). Methods: In this two-arm randomized controlled trial, participants were allocated 1:1 to a one-time 15-minute VR session or SOC referring to the participant's choice of available activity like watching television during chemotherapy. The primary objective was to assess the effect of VR on distress levels compared with the SOC group. Secondary objectives included assessing the preliminary effects of VR on anxiety, pain, and depressive symptoms, compared with the SOC group. Validated questionnaires were administered to both groups before and after the intervention. Outcomes were analyzed using analysis of covariance models adjusting for baseline values, age, and sex. SAS Studio 3.7 and R version 4.2 were used. Results: Sixty-eight participants completed the study (33 VR, 35 SOC). After adjustment for baseline distress, age, and sex, the VR group had significantly lower postintervention distress scores than the SOC group (adjusted mean difference 1.4 points, 95% CI, 0.34 to 2.45; P = .0102). The VR group had significantly lower postintervention depression and pain scores than the SOC group (adjusted mean differences: 1.14, P = .0055; and 1.5, P = .0032, respectively). Adjusted anxiety scores were lower with VR than SOC but did not reach statistical significance (mean difference 1.76; P = .0815). Conclusion: VR is a safe, innovative immersive intervention with the potential to reduce distress, pain, and depressive symptoms during chemotherapy. Larger longitudinal studies are needed to determine the optimal duration and frequency needed to reduce anxiety and maximize the durability of its effects.
- Top Cited PapersOpen Access
Minimal residual disease in solid tumors: Clinical applications and future directions
Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection. It enables real‐time disease monitoring, prognostication, and often therapeutic decision‐making. Two major ctDNA approaches exist, tumor‐informed and tumor‐agnostic, and they differ in sensitivity, specificity, and clinical feasibility. Recent clinical trials have supported a prognostic and predictive utility of ctDNA MRD in gastrointestinal, lung, breast, and other malignancies, with positive postoperative or post‐treatment MRD status correlating with higher recurrence risk and inferior survival outcomes. However, integration into clinical practice remains limited by challenges, including tumor heterogeneity, variable ctDNA shedding across tumor stage, location and timing, lack of standardized assay interpretation, and cost‐effectiveness concerns. Emerging technologies such as methylation‐based sequencing, ultra‐deep next‐generation sequencing, and machine learning–driven risk models hold promise for improving detection accuracy and clinical applicability. Ongoing clinical trials are expected to determine the impact of earlier MRD detection and intervention on patient outcomes, potentially supporting the broader adoption of ctDNA MRD. In this article, the authors reviewed the recent clinical applications, limitations and future directions of MRD in solid tumors.
Top Cited PapersOpen AccessMinimal residual disease in solid tumors: Clinical applications and future directions
Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection. It enables real‐time disease monitoring, prognostication, and often therapeutic decision‐making. Two major ctDNA approaches exist, tumor‐informed and tumor‐agnostic, and they differ in sensitivity, specificity, and clinical feasibility. Recent clinical trials have supported a prognostic and predictive utility of ctDNA MRD in gastrointestinal, lung, breast, and other malignancies, with positive postoperative or post‐treatment MRD status correlating with higher recurrence risk and inferior survival outcomes. However, integration into clinical practice remains limited by challenges, including tumor heterogeneity, variable ctDNA shedding across tumor stage, location and timing, lack of standardized assay interpretation, and cost‐effectiveness concerns. Emerging technologies such as methylation‐based sequencing, ultra‐deep next‐generation sequencing, and machine learning–driven risk models hold promise for improving detection accuracy and clinical applicability. Ongoing clinical trials are expected to determine the impact of earlier MRD detection and intervention on patient outcomes, potentially supporting the broader adoption of ctDNA MRD. In this article, the authors reviewed the recent clinical applications, limitations and future directions of MRD in solid tumors.